Latest Content

Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.

Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.

To guide public health and vaccination strategies, researchers assessed a variety of factors regarding community-acquired pneumonia and its causes.

Highlighting the clinical impact of the pharmacy profession, we caught up with pharmacists of various types to get their perspectives on the evolution of pharmacy.

A newly erected Women’s Health Division within NIH will work in tandem with the Office of Research on Women’s Health.

Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.

Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.

Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.

Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.

Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.

With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.

Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.

Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.

Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.

AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.

Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

Cheri Schmit explains how pharmacists' roles are growing beyond dispensing into prevention, test-and-treat, and artificial intelligence-supported patient care.

In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.

Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.

Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.

Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.

During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.

Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.

Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.

The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.

Melissa McGivney, PharmD, FAPhA, FCCP, helps celebrate American Pharmacists Month and the innovation driving the profession forward amongst US communities.

Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.